Advertisement

Therapy for Patients not Eligible for Autologous Transplant

  • Bringhen Sara
  • Palumbo Antonio
Part of the Contemporary Hematology book series (CH)

Introduction

High-dose therapy supported by autologous stem cell transplant is considered a category 1 recommendation for newly diagnosed multiple myeloma (MM) patients.1 Currently, MM is the most common indication for autologous transplant, with ~ 4,500 transplants performed yearly in North America (Center for International Blood and Marrow Transplant Research [CIBMTR] data) and 5,300 in Europe.2Therefore, one of the first steps in choosing an initial therapy for symptomatic MM patients is to determine whether they would be candidates for stem cell transplant. The criteria to define eligibility for stem cell transplant include comorbidities, age, and performance status. Abnormal cardiac, pulmonary, renal, and liver functions are generally considered exclusion criteria for transplant protocols. Sixty-five years of age is commonly the higher limit age used to define eligible patients. However, it should be noted that advanced age and renal dysfunction are not absolute...

Keywords

Overall Survival Multiple Myeloma Peripheral Neuropathy Maintenance Therapy Induction Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Supported in part by the Universitá degli Studi di Torino, Fondazione Neoplasie Sangue Onlus, Associazione Italiana Leucemie, Compagnia di S Paolo, Fondazione Cassa di Risparmio di Torino, Ministero dell'Universitá della Ricerca (MIUR), and Consiglio Nazionale delle Ricerche (CNR), Italy.

References

  1. 1.
    Anderson KC, Alsina M, Bensinger W, et al. National Comprehensive Cancer Network(NCCN). Multiple myeloma. Clinical practice guidelines in oncology. J NatI Compr Canc Netw 2007;5:118–47.Google Scholar
  2. 2.
    Gratwohl A, Baldomero H, Frauendorfer K, Urbano-lspizua A. EBMT activity survey2004 and changes in disease indication over the past 15 Years. Bone Marrow Transplant 2006;37: 1069–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value onoutcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007;39:605–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Lenhoff S, Hjorth M, Holmberg E, et al. Impact of survival of high-dose therapy with autologous stem cell support in patients younger than 60 Years with newly diagnosed multiple myeloma: A population-based study. Blood 2000;95:7–11.PubMedGoogle Scholar
  5. 5.
    Morris TCM, Velangi M, Jackson G, Marks DI, Ranaghan L. Less than half of patientsaged 65 Years or under with myeloma proceed to transplantation: Results of a two region population-based survey. Br J Haematol 2005;128:510–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Greipp PR, San Miguel J, Dune BG, et al., International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyper-diploidmyeloma: Effects of chromosome 13 deletions and IgH translocations. Leukemia 2006;20:807–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–57.PubMedCrossRefGoogle Scholar
  9. 9.
    Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23:7069–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the lntergroupe Francophone du Myelome. Blood 2007; 109:3489–95.CrossRefGoogle Scholar
  11. 11.
    Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680–85.PubMedCrossRefGoogle Scholar
  12. 12.
    GROUP MTC. Combination chemotherapy versus MP as treatment of multiple myeloma: An overview of 6,633 patients from 27 randomised trials. J Clin Oncol 1998; 16:3832–42.Google Scholar
  13. 13.
    Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887–90.PubMedGoogle Scholar
  14. 14.
    Segeren CM, Sonneveld P, Van Der Holt B, et al. Vincristine, doxorubicin and dexam-ethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004 ; 127:159–164.PubMedCrossRefGoogle Scholar
  16. 16.
    Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus mel-phalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untrea-tedindolent or smoldering multiple myeloma. Leukemia 2001;15:1274–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16–19.PubMedCrossRefGoogle Scholar
  19. 19.
    Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology Group. Phase Ill clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Ludwig H, Drach J, Tothová E, et al. Thalidomide-dexamethasone versus melpha-lan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. Blood 2005;106:782a.Google Scholar
  21. 21.
    Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006;367:825–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Facon T, Mary J, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem-cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007;370:1209–18.PubMedCrossRefGoogle Scholar
  23. 23.
    Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 Years with newly diagnosed multiple myeloma. Blood 2006:108:2159–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Sidra G, Williams CD, Russet NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006;91:862–63.PubMedGoogle Scholar
  25. 25.
    Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N EngI J Med 2006;354:1021–30.CrossRefGoogle Scholar
  26. 26.
    Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, thalido-mide in elderly patients with multiple myeloma: up-dated results of a randomized, controlled trial. Blood 2008;doi:10.1182/Blood-2008-04-149427.Google Scholar
  27. 27.
    Palumbo A, Bringhen S, Falco P, et al. Time to first progression, but not ~2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110:824–29.PubMedCrossRefGoogle Scholar
  28. 28.
    Rajkumar SV, Hayman SR, Lacy MQ, Combination therapy with lenal-idomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005 ; 106 : 4050–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Lacy M, Gertz M, Dispenzieri A, et al. Long term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179–84PubMedCrossRefGoogle Scholar
  30. 30.
    Rajkumar V, Jacobus S, Callander N, et al. A randomized phase III trial of lenal-idomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexam-ethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Blood 2006;108:799a.Google Scholar
  31. 31.
    Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Jagannath S, Dune BC, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–83.PubMedCrossRefGoogle Scholar
  33. 33.
    Mateos MV, Hernandez JM, Hernandez MI, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multi-center phase I/Il study. Blood 2006;108:2165–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bort-ezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol 2005; 129:755–62.PubMedCrossRefGoogle Scholar
  35. 35.
    Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164–68.PubMedCrossRefGoogle Scholar
  36. 36.
    Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319–30.PubMedCrossRefGoogle Scholar
  37. 37.
    Bennet CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associ-ated thromboembolism among patients with cancer. JAMA 2006;296:2558–60.CrossRefGoogle Scholar
  38. 38.
    Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117:508–15.PubMedCrossRefGoogle Scholar
  39. 39.
    Lonial S, Wailer EK, Richardson PG, et al. SUMMIT/CREST investigators risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777–84.PubMedCrossRefGoogle Scholar
  40. 40.
    Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767–72.PubMedGoogle Scholar
  41. 41.
    Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and rever-sibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–20.PubMedCrossRefGoogle Scholar
  42. 42.
    Mihelic R, Kaufman JL, Lonial S. Maintenance therapy in multiple myeloma. Leukemia 2007;21:1150–57.PubMedCrossRefGoogle Scholar
  43. 43.
    Fritz E, Ludwig H. Interferon-{alpha} treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000;11:1427–36.PubMedCrossRefGoogle Scholar
  44. 44.
    The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020–34.CrossRefGoogle Scholar
  45. 45.
    Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163–68.PubMedCrossRefGoogle Scholar
  46. 46.
    Shustik C, Belch A, Robinson S, et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clinical Trials Group Study: MY.7. J Clin Oncol 2004;22 (Suppl 15): 651 Oa.Google Scholar
  47. 47.
    Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289–94.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Bringhen Sara
    • 1
  • Palumbo Antonio
    • 1
  1. 1.Divisione di Ematologia dell'Universita di TorinoItaly

Personalised recommendations